Global Biopharmaceutical Market Report & Forecast (2018-2023)
The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.
Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.
Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.
The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.
The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.
IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2018-2023)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2023. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.
What We Have Achieved in this Report?
Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market
Key Aspects Analyzed:
Driving Factors
Restraining Factors
Market Opportunities
Threats
Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
Regions/Countries Covered:
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins
Focus of the Analysis for Each Country:
Total Market Performance
Performance of Various Classes
Performance of Top Players
Market Forecast
Key Questions Answered in this Report:
Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.
Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.
The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.
The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.
IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2018-2023)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2023. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.
What We Have Achieved in this Report?
Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market
Key Aspects Analyzed:
Driving Factors
Restraining Factors
Market Opportunities
Threats
Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
Regions/Countries Covered:
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins
Focus of the Analysis for Each Country:
Total Market Performance
Performance of Various Classes
Performance of Top Players
Market Forecast
Key Questions Answered in this Report:
- What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
- What are the key opportunities and threats faced by the biopharmaceutical industry?
What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years? - Which are the world’s largest biopharmaceutical markets?
- Which are the world’s fastest growing biopharmaceutical markets?
- What is the structure and composition of various biopharmaceutical markets across the globe?
- Which are the world’s largest biopharmaceutical segments?
- Which are the world’s fastest growing biopharmaceutical segments?
Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?
1 PREFACE
2 RESEARCH METHODOLOGY AND MARKET DEFINITIONS
3 EXECUTIVE SUMMARY
4 INTRODUCTION
5 GLOBAL BIOPHARMACEUTICAL MARKET
5.1 Market Performance and Forecast
5.1.1 Current Performance (2010-2017)
5.1.2 Market Forecast (2018-2023)
5.2 Market by Region
5.2.1 Current Performance (2010-2017)
5.2.2 Market Forecast (2018-2023)
5.3 Market by Indication
5.3.1 Autoimmune Diseases
5.3.2 Oncology
5.3.3 Metabolic Disorders
5.3.4 Others
5.4 Market by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2010-2017)
5.4.1.2 Market Forecast (2018-2023)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2010-2017)
5.4.2.2 Market Forecast (2018-2023)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2010-2017)
5.4.3.2 Market Forecast (2018-2023)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
5.6 Value Chain Analysis
5.7 Porter’s Five Forces Analysis
5.7.1 Overview
5.7.2 Bargaining Power of Buyers
5.7.3 Bargaining Power of Suppliers
5.7.4 Degree of Rivalry
5.7.5 Threat of New Entrants
5.7.6 Threat of Substitutes
6 NORTH AMERICA
6.1 United States
6.1.1 Market Performance (2010-2017)
6.1.2 Market by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Top Players
6.1.4 Market Forecast (2018-2023)
6.2 Canada
6.2.1 Market Performance (2010-2017)
6.2.2 Market by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.2.3 Purified Proteins
6.2.3 Top Players
6.2.4 Market Forecast (2018-2023)
7 LATIN AMERICA
7.1 Mexico
7.1.1 Market Performance (2010-2017)
7.1.2 Market by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Top Players
7.1.4 Market Forecast (2018-2023)
7.2 Brazil
7.2.1 Market Performance (2010-2017)
7.2.2 Market by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Top Players
7.2.4 Market Forecast (2018-2023)
7.3 Argentina
7.3.1 Market Performance (2010-2017)
7.3.2 Market by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Top Players
7.3.4 Market Forecast (2018-2023)
8 EUROPE
8.1 Germany
8.1.1 Market Performance (2010-2017)
8.1.2 Market by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Top Players
8.1.4 Market Forecast (2018-2023)
8.2 France
8.2.1 Market Performance (2010-2017)
8.2.2 Market by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Top Players
8.2.4 Market Forecast (2018-2023)
8.3 Italy
8.3.1 Market Performance (2010-2017)
8.3.2 Market by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Top Players
8.3.4 Market Forecast (2018-2023)
8.4 Spain
8.4.1 Market Performance (2010-2017)
8.4.2 Market by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Top Players
8.4.4 Market Forecast (2018-2023)
8.5 United Kingdom
8.5.1 Market Performance (2010-2017)
8.5.2 Market by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Top Players
8.5.4 Market Forecast (2018-2023)
8.6 Russia
8.6.1 Market Performance (2010-2017)
8.6.2 Market by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Top Players
8.6.4 Market Forecast (2018-2023)
8.7 Turkey
8.7.1 Market Performance (2010-2017)
8.7.2 Market by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Top Players
8.7.4 Market Forecast (2018-2023)
9 ASIA PACIFIC
9.1 Japan
9.1.1 Market Performance (2010-2017)
9.1.2 Market by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Top Players
9.1.4 Market Forecast (2018-2023)
9.2 China
9.2.1 Market Performance (2010-2017)
9.2.2 Market by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Top Players
9.2.4 Market Forecast (2018-2023)
9.3 Australia
9.3.1 Market Performance (2010-2017)
9.3.2 Market by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Top Players
9.3.4 Market Forecast (2018-2023)
9.4 South Korea
9.4.1 Market Performance (2010-2017)
9.4.2 Market by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Top Players
9.4.4 Market Forecast (2018-2023)
9.5 India
9.5.1 Market Performance (2010-2017)
9.5.2 Market by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Top Players
9.5.4 Market Forecast (2018-2023)
9.6 Indonesia
9.6.1 Market Performance (2010-2017)
9.6.2 Market by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Top Players
9.6.4 Market Forecast (2018-2023)
10 SWOT ANALYSIS
10.1 Strengths
10.2 Weaknesses
10.3 Opportunities
10.4 Threats
2 RESEARCH METHODOLOGY AND MARKET DEFINITIONS
3 EXECUTIVE SUMMARY
4 INTRODUCTION
5 GLOBAL BIOPHARMACEUTICAL MARKET
5.1 Market Performance and Forecast
5.1.1 Current Performance (2010-2017)
5.1.2 Market Forecast (2018-2023)
5.2 Market by Region
5.2.1 Current Performance (2010-2017)
5.2.2 Market Forecast (2018-2023)
5.3 Market by Indication
5.3.1 Autoimmune Diseases
5.3.2 Oncology
5.3.3 Metabolic Disorders
5.3.4 Others
5.4 Market by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2010-2017)
5.4.1.2 Market Forecast (2018-2023)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2010-2017)
5.4.2.2 Market Forecast (2018-2023)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2010-2017)
5.4.3.2 Market Forecast (2018-2023)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
5.6 Value Chain Analysis
5.7 Porter’s Five Forces Analysis
5.7.1 Overview
5.7.2 Bargaining Power of Buyers
5.7.3 Bargaining Power of Suppliers
5.7.4 Degree of Rivalry
5.7.5 Threat of New Entrants
5.7.6 Threat of Substitutes
6 NORTH AMERICA
6.1 United States
6.1.1 Market Performance (2010-2017)
6.1.2 Market by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Top Players
6.1.4 Market Forecast (2018-2023)
6.2 Canada
6.2.1 Market Performance (2010-2017)
6.2.2 Market by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.2.3 Purified Proteins
6.2.3 Top Players
6.2.4 Market Forecast (2018-2023)
7 LATIN AMERICA
7.1 Mexico
7.1.1 Market Performance (2010-2017)
7.1.2 Market by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Top Players
7.1.4 Market Forecast (2018-2023)
7.2 Brazil
7.2.1 Market Performance (2010-2017)
7.2.2 Market by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Top Players
7.2.4 Market Forecast (2018-2023)
7.3 Argentina
7.3.1 Market Performance (2010-2017)
7.3.2 Market by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Top Players
7.3.4 Market Forecast (2018-2023)
8 EUROPE
8.1 Germany
8.1.1 Market Performance (2010-2017)
8.1.2 Market by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Top Players
8.1.4 Market Forecast (2018-2023)
8.2 France
8.2.1 Market Performance (2010-2017)
8.2.2 Market by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Top Players
8.2.4 Market Forecast (2018-2023)
8.3 Italy
8.3.1 Market Performance (2010-2017)
8.3.2 Market by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Top Players
8.3.4 Market Forecast (2018-2023)
8.4 Spain
8.4.1 Market Performance (2010-2017)
8.4.2 Market by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Top Players
8.4.4 Market Forecast (2018-2023)
8.5 United Kingdom
8.5.1 Market Performance (2010-2017)
8.5.2 Market by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Top Players
8.5.4 Market Forecast (2018-2023)
8.6 Russia
8.6.1 Market Performance (2010-2017)
8.6.2 Market by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Top Players
8.6.4 Market Forecast (2018-2023)
8.7 Turkey
8.7.1 Market Performance (2010-2017)
8.7.2 Market by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Top Players
8.7.4 Market Forecast (2018-2023)
9 ASIA PACIFIC
9.1 Japan
9.1.1 Market Performance (2010-2017)
9.1.2 Market by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Top Players
9.1.4 Market Forecast (2018-2023)
9.2 China
9.2.1 Market Performance (2010-2017)
9.2.2 Market by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Top Players
9.2.4 Market Forecast (2018-2023)
9.3 Australia
9.3.1 Market Performance (2010-2017)
9.3.2 Market by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Top Players
9.3.4 Market Forecast (2018-2023)
9.4 South Korea
9.4.1 Market Performance (2010-2017)
9.4.2 Market by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Top Players
9.4.4 Market Forecast (2018-2023)
9.5 India
9.5.1 Market Performance (2010-2017)
9.5.2 Market by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Top Players
9.5.4 Market Forecast (2018-2023)
9.6 Indonesia
9.6.1 Market Performance (2010-2017)
9.6.2 Market by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Top Players
9.6.4 Market Forecast (2018-2023)
10 SWOT ANALYSIS
10.1 Strengths
10.2 Weaknesses
10.3 Opportunities
10.4 Threats
LIST OF FIGURES
Figure 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 2: Complexity of Biopharmaceuticals
Figure 3: Sources of Biopharmaceuticals
Figure 4: Global: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 5: Global: Biopharmaceutical Market Forecast: Value trends (in Million US$), 2018-2023
Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2017
Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2023
Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2017
Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2018-2023
Figure 11: Global: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2018-2023
Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2018-2023
Figure 17: Global: Purified Proteins Market (in Million US$), 2010-2017
Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 202-2023
Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %),
Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
Figure 22: Biopharmaceutical Industry: Porter’s Five Forces Analysis
Figure 23: United States: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 25: United States: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 29: United States: Purified Proteins Market (in Million US$), 2010-2017
Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 49: Mexico: Purified Proteins Market (in ‘000 US$), 2010-2017
Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 59: Brazil: Purified Proteins Market (in Million US$), 2010-2017
Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 69: Argentina: Purified Proteins Market (in Million US$), 2010-2017
Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 79: Germany: Purified Proteins Market (in Million US$), 2010-2017
Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 84: France: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 86: France: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 90: France: Purified Proteins Market (in Million US$), 2010-2017
Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 100: Italy: Purified Proteins Market (in Million US$), 2010-2017
Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 110: Spain: Purified Proteins Market (in Million US$), 2010-2017
Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 115: UK: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 117: UK: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 121: UK: Purified Proteins Market (in Million US$), 2010-2017
Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 132: Russia: Purified Proteins Market : (in Million US$), 2010-2017
Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 142: Turkey: Purified Proteins Market (in Million US$), 2010-2017
Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 152: Japan: Purified Proteins Market (in Million US$), 2010-2017
Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 154: Japan: Biopharmaceutical Market Forecast : Value trend(in Million US$), 2018-2023
Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 156: China: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 158: China: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 162: China: Purified Proteins Market : (in Million US$), 2010-2017
Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 173: Australia: Purified Proteins Market (in Million US$), 2010-2017
Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2017
Figure 183: South Korea: Purified Proteins Market (in Million US$), 2010-2017
Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 188: India: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 190: India: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 193: India: Purified Proteins Market (in Million US$), 2010-2017
Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2017
Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2017
Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
Figure 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 2: Complexity of Biopharmaceuticals
Figure 3: Sources of Biopharmaceuticals
Figure 4: Global: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 5: Global: Biopharmaceutical Market Forecast: Value trends (in Million US$), 2018-2023
Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2017
Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2023
Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2017
Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2018-2023
Figure 11: Global: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2018-2023
Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2018-2023
Figure 17: Global: Purified Proteins Market (in Million US$), 2010-2017
Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 202-2023
Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %),
Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
Figure 22: Biopharmaceutical Industry: Porter’s Five Forces Analysis
Figure 23: United States: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 25: United States: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 29: United States: Purified Proteins Market (in Million US$), 2010-2017
Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 49: Mexico: Purified Proteins Market (in ‘000 US$), 2010-2017
Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 59: Brazil: Purified Proteins Market (in Million US$), 2010-2017
Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 69: Argentina: Purified Proteins Market (in Million US$), 2010-2017
Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 79: Germany: Purified Proteins Market (in Million US$), 2010-2017
Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 84: France: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 86: France: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 90: France: Purified Proteins Market (in Million US$), 2010-2017
Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2017
Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 100: Italy: Purified Proteins Market (in Million US$), 2010-2017
Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 110: Spain: Purified Proteins Market (in Million US$), 2010-2017
Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 115: UK: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 117: UK: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 121: UK: Purified Proteins Market (in Million US$), 2010-2017
Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 132: Russia: Purified Proteins Market : (in Million US$), 2010-2017
Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 142: Turkey: Purified Proteins Market (in Million US$), 2010-2017
Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 152: Japan: Purified Proteins Market (in Million US$), 2010-2017
Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 154: Japan: Biopharmaceutical Market Forecast : Value trend(in Million US$), 2018-2023
Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 156: China: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 158: China: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 162: China: Purified Proteins Market : (in Million US$), 2010-2017
Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 173: Australia: Purified Proteins Market (in Million US$), 2010-2017
Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2017
Figure 183: South Korea: Purified Proteins Market (in Million US$), 2010-2017
Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2017
Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 188: India: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 190: India: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 193: India: Purified Proteins Market (in Million US$), 2010-2017
Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2010-2017
Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2010-2017
Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2010-2017
Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2017
Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2010-2017
Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2017
Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2018-2023
Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2023
Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2017
Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2017 & 2023
Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2017
Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
LIST OF TABLES
Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
Table 2: Global: Biopharmaceutical Market: SWOT Analysis
Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2017 & 2023
Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2010-2017
Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2018-2023
Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2017
Table 9: Mode of Administration of Popular Biotech Drugs
Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
Table 2: Global: Biopharmaceutical Market: SWOT Analysis
Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2017 & 2023
Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2010-2017
Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2018-2023
Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2017
Table 9: Mode of Administration of Popular Biotech Drugs
